- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Piqray, Vijoice
Synonyms :
Alpelisib
Class :
Antineoplastics and PI3K Inhibitors
Dosage Forms & Strengths
Tablet-Piqray
50mg
150mg
200mg
Tablet-Vijoice
50mg
125mg
200mg
300
mg
Orally
once a day
;Treatment continued until the disease progression, or unacceptable toxicity occurs
The dose recommended for fulvestrant is 500 mg given orally on days 1, 15, and 29, and once monthly thereafter
Note:
Alpelisib with fulvestrant combination used for the treatment of PIK3CAmutated, postmenopausal women, and men, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer and recommended by FDA
pIK CA Related Overgrowth Spectrum
250
mg
Orally
once a day
Treatment continued until the disease progression, or unacceptable toxicity occurs
Dose Adjustments
Renal Dose Adjustments:
no adjustment recommended for mild and moderate renal impairment
data is not available for severe renal impairment
Liver Dose Adjustments:
no adjustment recommended
Dosage Forms & Strengths
Tablet-Vijoice
50mg
125mg
pIK CA Related Overgrowth Spectrum
For patients<2 years, the safety and efficacy are not established
For patients ≥2 years with PROS who require systemic therapy
For 2 to < 6 years
50 mg taken orally once a day
treatment continued until the disease progression or unacceptable toxicity occurs
For 6 to <18 years
The Initial dose is 50 mg, taken orally once a day
later after 24 weeks, start increasing the dose up to 125 mg once a day for response optimization
Treatment continued until the disease progression, or unacceptable toxicity occurs
For ≥18 years
consider a gradually increasing dose up to 250 mg taken orally once a day
when both drugs are combined, there may be an increase in the serum concentration of alpelisib
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of P-glycoprotein/ABCB1 Inhibitors
may increase the serum concentration
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of BCRP/ABCG2 Inhibitors
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of BCRP/ABCG2 inhibitors
may enhance the serum concentration of BCRP/ABCG2 Inhibitors
may enhance the serum concentration of P-glycoprotein/ABCB1 Inhibitors
may enhance the serum concentration of BCRP/ABCG2 Inhibitors
may enhance the serum concentration of BCRP/ABCG2 Inhibitors
when both drugs are combined, there may be an increasing effect of alpelisib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased metabolism of acalabrutinib
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
when both drugs are combined, there may be a reduced level of the serum concentration of atazanavir
when both drugs are combined, there may be a decreased level of serum concentration of bosentan
when both drugs are combined, there may be an increasing effect of alpelisib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased metabolism of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased metabolism of erdafitinib
when both drugs are combined, there may be a decreased levels of serum concentration of etravirine
when both drugs are combined, there may be a decreased metabolism of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased metabolism of ivosidenib
when both drugs are combined, there may be a decreased metabolism of alpelisib
when both drugs are combined, there may be a decreased metabolism of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be a decreased metabolism of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of lonafarnib
when both drugs are combined, there may be a decreased metabolism of alpelisib
when both drugs are combined, there may be an increased metabolism of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
It may enhance the effect when combined with tafamidis meglumine
nafcillin will decrease the effect of action of alpelisib by synergism.
the effect of alpelisib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased risk of adverse effects
when both drugs are combined, there may be a decreased effect of alpelisib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
alpelisib and lapatinib will increase the effect of each other when used simultaneously
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of alpelisib
both the drugs, when used in combination, increase the effect of one another
regorafenib, when used in combination with alpelisib, increases the impact or level of each other
It may diminish the level when combined with efavirenz by affecting CYP3A4 metabolism
when both drugs are combined, there may be an increased metabolism of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of bexarotene
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be a decreased levels of serum concentration of celecoxib
when both drugs are combined, there may be a decreased level of serum concentration of chlorpropamide
when both drugs are combined, there may be a decreased level of serum concentration of diclofenac
when both drugs are combined, there may be a decreased level of serum concentration of dronabinol
when both drugs are combined, there may be a decreased metabolism of elagolix
when both drugs are combined, there may be a decreased level of serum concentration of glipizide
when both drugs are combined, there may be a decreased level of serum concentration of glyburide
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be a decreased level of serum concentration of ketamine
when both drugs are combined, there may be a decreased level of serum concentration of lacosamide
when both drugs are combined, there may be a decreased level of serum concentration of lesinurad
when both drugs are combined, there may be a decreased level of serum concentration of losartan
when both drugs are combined, there may be a decreased level of serum concentration of warfarin
when both drugs are combined, there may be a decreased level of the serum concentration of zafirlukast
Combining tegafur with alpelisib can reduce tegafur’s metabolism
when both drugs are combined, there may be an increased metabolism of etoposide
when both drugs are combined, there may be an increased metabolism of vincristine
when both drugs are combined, there may be an increased metabolism of paclitaxel
may decrease the level by affecting hepatic enzyme CYP2C9 metabolism
may decrease the serum concentration
It may diminish the metabolism when combined with nilvadipine
when both drugs are combined, there may be an increased metabolism of alpelisib
when both drugs are combined, there may be a decreased level of the serum concentration of dapsone
Adverse drug reactions:
Frequency defined
>10%
Lymphocyte count decreased
Hemoglobin decreased
Activated partial thromboplastin time prolonged
Platelet count decreased
Glucose increased
Hyperglycemia
Weight loss
Calcium (corrected) decreased
Glucose decreased
Potassium decreased
Albumin decreased
Magnesium decreased
Urinary tract infection
0.1-1%
Anaphylaxis
Anaphylactic shock
Dyspnea
Flushing
Rash
Fever
Tachycardia
Osteonecrosis of the jaw
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Alpelisib is an anti-cancer agent responsible for stopping cancerous growth with other medicine like fulvestrant.
It is used to treat hormone receptor-positive HR, human epidermal growth factor receptor 2- negative, PIK3C amutated, or any metastatic cancer.
Alpelisib interacts and interferes in the cancer cell growth, which in due course may get destroyed.
There are various unwanted effects as alpelisib also reacts with the healthy normal growing cells. You should consult your doctor if anything persists.
The drug interactions for the same are provided in the different sections herein.
If you have a specific medical condition like respiratory disorder or diabetes, you should inform your physician before starting the treatment.
Follow a proper dose regimen and do not start/stop the medication without consulting the physician.
Alpelisib may cause disturbance in glycaemic blood level, pneumonitis, diarrhea, and dehydration. Take plenty of fluids during this therapy.
Store the medication at room temperature and away from sunlight/moisture.
ADVERTISEMENT
